Showing results (551-560 of 601) with videos related to
Sort By:
Pageof 61
Lancet (London, England)|September 10, 2019
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, et al.Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.Acta Neuropathologica|June 18, 2024
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravisChristina B Schroeter, Christopher Nelke, Frauke Stascheit, et al.Multiple Sclerosis and Related Disorders|December 2, 2025
Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settingsNick Rijke, Bassem I Yamout, Deanna Saylor, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 23, 2022
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumabSaskia Räuber, Melanie Korsen, Niklas Huntemann, et al.The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.Multiple Sclerosis and Related Disorders|April 3, 2022
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questionsPaola Zaratin, Patrick Vermersch, Maria Pia Amato, et al.Journal of Neurology|July 11, 2024
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Christina B Schroeter, Felix Kohle, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 31, 2022
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic ModelsMichael Dietrich, Christina Hecker, Elodie Martin, et al.Pageof 61